Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled multicenter study of Qingjiang Hewei Granules for non-erosive reflux disease
CTR20251376Phase 2Active
- Sponsor
- Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-erosive Gastroesophageal Reflux Disease (NERD) comparing Qingjiang Hewei Granules with Placebo (2 arms). Primary endpoint: Week 8 response rate in VAS scores for heartburn and regurgitation symptoms. Started Jun 2025; status: active.
02
Drugs
Qingjiang Hewei Granules
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on CTR20251376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251376.